Trump’s order of signs in order to stimulate pharmaceutical manufacturing in the United States

In the midst of continuous anticipation on prices on pharmaceutical products, President Trump signed a decree designed on Monday to reduce regulatory obstacles and return faster than pharmaceutical companies to manufacture their products in the United States, the move also includes plans to exert more pressure on foreign drug manufacturers to comply with quality control inspections.

At the top of the list is a mandate for the Food and Drug Administration to reduce the time necessary to approve the domestic pharmaceutical manufacturing factories. The agency aims to eliminate “duplicate and useless requirements”, rationalizes magazines and work with “national manufacturers to provide support before the facilities start to work”. The objectives were not mentioned in order.

At the same time, the Environmental Protection Agency was ordered to accelerate its approval of the construction of installations for the manufacture of drugs, active pharmaceutical ingredients and related raw materials. And federal agencies delivering permits for a national manufacturing plant must designate a single contact point to coordinate permits with the support of the White House management and budget office.